# Diabetes Research Hub — Monitor Report
**Date:** 2026-03-31
**Automated scan by:** Cowork Scheduled Task (diabetes-hub-monitor)

---

## File System Status

| File | Last Modified | Status |
|------|--------------|--------|
| hub_monitor_report.md | 2026-03-31 02:05 | Fresh (today) |
| clinical_trials_latest.json | 2026-03-31 02:04 | Fresh (today) |
| pubmed_recent_latest.json | 2026-03-31 02:05 | Fresh (today) |
| literature_gap_data.json | 2026-03-15 00:45 | **STALE — 16 days old (past 14-day threshold)** |
| literature_gap_report.md | 2026-03-30 03:08 | Fresh (yesterday) |
| hub_monitor_state.json | 2026-03-31 02:05 | Fresh (today) |

**Hub monitor detected:** 562 total files tracked, 47 new files, 46 modified files, 0 removed.

**Significant new files since last scan:**
- `10_Questions_Self_Audit.md` (58.7 KB) — New self-audit document
- `Claims_Gap_Analysis.md` (9.0 KB) — New claims gap analysis
- `GKA_PMID_Verification_Report.md` (11.0 KB) — New GKA verification report
- `PMID_Quick_Reference_Table.csv` (3.8 KB) — New PMID quick reference
- `ROADMAP_Fix_Three_Vulnerabilities.md` (18.3 KB) — New vulnerability remediation roadmap
- `Analysis/Scripts/verify_before_deploy.py` (20.2 KB) — New pre-deployment verification script
- 34 new verification report JSON files in `Analysis/Results/verification_reports/`
- 4 dashboards quarantined in `Dashboards/_quarantine/` (CART_Access_Barriers, GKA_Pricing, Generic_Drug_Catalog, Research_Paths)

**Review flags:** 7 result files are older than 14 days and may need refresh.

---

## Clinical Trial Changes

### Snapshot Comparison (2026-03-30 → 2026-03-31)

| Metric | Count |
|--------|-------|
| New trials | 2 |
| Removed trials | 1 |
| Status changes | 2 |
| New results posted | 0 |

**Status Changes (significant):**
- **NCT07400653:** NOT_YET_RECRUITING → **RECRUITING** — "A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity" (Pfizer obesity compound now actively enrolling)
- **NCT07211126:** NOT_YET_RECRUITING → **RECRUITING** — "The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes" (Tandem Diabetes Care real-world AID study now recruiting)

### Key Recruiting Phase 3 Trials (Priority Watch List)

**Total recruiting Phase 3 trials: 40** (down from ~44 in yesterday's report — likely due to snapshot recounting methodology)

| NCT ID | Title | Sponsor | Status |
|--------|-------|---------|--------|
| NCT04786262 | VX-880 Safety, Tolerability, and Efficacy in T1D | **Vertex Pharmaceuticals** | RECRUITING |
| NCT06832410 | VX-880 in T1D with Kidney Transplant | **Vertex Pharmaceuticals** | RECRUITING |
| NCT07222137 | Baricitinib for Delay of Stage 3 T1D | **Eli Lilly** | RECRUITING |
| NCT07222332 | Baricitinib to Preserve Beta Cell Function | **Eli Lilly** | RECRUITING |
| NCT06972472 | Orforglipron in Obesity/Overweight | **Eli Lilly** | RECRUITING |
| NCT06993792 | Orforglipron Master Protocol | **Eli Lilly** | RECRUITING |
| NCT07076199 | Insulin Icodec (weekly insulin) | **Novo Nordisk** | RECRUITING |
| NCT07271251 | Oral Semaglutide Formulations | **Novo Nordisk** | RECRUITING |

### Overall Trial Portfolio (757 total — +1 net from yesterday)

| Category | Count | Change |
|----------|-------|--------|
| T1D Cure & Cell Therapy | 154 | +1 |
| T1D Immunotherapy & Prevention | 71 | — |
| T2D Novel Therapies (Phase 2-3) | 137 | — |
| Diabetes Technology (Devices) | 218 | — |
| Recently Completed with Results | 250 | +1 |

---

## PubMed Highlights

### Publication Volume (Last 30 Days) — 131 unique papers across 15 domains

| Domain | Total Papers | Trend vs. Yesterday |
|--------|-------------|---------------------|
| Diabetes AI/ML | 221 | **RECOVERED** (was 0 yesterday — API issue resolved) |
| Diabetes Microbiome | 172 | Stable (was 172) |
| T2D GLP-1 New | 164 | Slight increase (was 161) |
| Diabetes Biomarker | 145 | Stable (was 144) |
| Diabetes Health Equity | 77 | Stable |
| Diabetes Complications New | 60 | Slight increase (was 58) |
| T2D Remission | 56 | Slight increase (was 54) |
| Diabetes Multi-Omics | 49 | Stable |
| Diabetes Gene Therapy | 45 | Stable |
| T1D Immunotherapy | 27 | **RECOVERED** (was 0 yesterday) |
| Closed Loop AP | 23 | Stable |
| T1D Stem Cell Cure | 19 | Stable |
| LADA New Research | 9 | **RECOVERED** (was 0 yesterday) |
| Diabetes Drug Repurpose | 6 | Stable |
| Diabetes Epigenetics | 4 | Stable |

**Key observation:** The AI/ML, T1D Immunotherapy, and LADA domains that showed 0 results yesterday have recovered. Yesterday's zeroes were indeed a PubMed API issue, not a real activity drop.

### Cross-Domain Papers (7 total — highest priority)

| PMID | Title | Domains | Significance |
|------|-------|---------|-------------|
| **41907858** | Oral and cardiometabolic health through the lens of biobanks and large-scale epidemiologic research | T2D Remission + Microbiome + Multi-Omics | **Triple-domain cross-over** — aligns with Tier 1 Multi-Omics Biomarker Integration |
| **41909676** | Unveiling the immune microenvironment in diabetic nephropathy: from mechanisms to therapeutics | Microbiome + Multi-Omics | Cross-domain immunity/complications |
| **41910593** | Whole Metagenomic Profiling Identifies a Gut Microbial Signature for Chronic Pancreatitis via ML | AI/ML + Microbiome | ML applied to microbiome data — Tier 1 alignment |
| **41872174** | Antigen-specific immunotherapy with CD4 T-cell approach for T1D | Stem Cell Cure + Immunotherapy | Key islet transplant + immunotherapy bridge paper |
| **41899527** | Systems-Level Transcriptomic Integration: T2D + HBV → Cholangiocarcinoma | Biomarker + Drug Repurpose | Tier 1 Drug Repurposing alignment |
| **41878122** | Nanotechnology-Based Treatment for Ophthalmic Diseases | Gene Therapy + Complications | Novel delivery approaches for diabetic retinopathy |
| **41850943** | Corrigendum: ProHCL patient-reported outcomes in T1D | Immunotherapy + Closed Loop AP | Minor (corrigendum) |

### New Papers Since Yesterday (49 new, 24 dropped from rolling window)

Notable additions: 3 new cross-domain papers appeared (PMIDs 41907858, 41909676, 41910593). This is an increase from 0 new cross-domain papers yesterday.

### Key Therapy Mentions

| PMID | Title | Therapy | Note |
|------|-------|---------|------|
| 41796109 | Teplizumab in Stage 2 T1D: Clinical Practice Experience | **Teplizumab** | Real-world clinical experience report — especially relevant given FDA sNDA decision April 29 |

No papers in latest snapshot mentioned zimislecel, orforglipron, retatrutide, CagriSema, or baricitinib in titles/abstracts.

---

## Gap Analysis Summary

**Data freshness:** Gap data is from 2026-03-15 — **now 16 days old, past the 14-day stale threshold. Re-run is overdue.**

### Top 5 Under-Researched Intersections (by Gap Score)

| Rank | Domain Pair | Gap Score | Joint Pubs | Tier 1 Alignment |
|------|------------|-----------|------------|------------------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 | Yes — Literature Synthesis |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 | Yes — Drug Repurposing Screening |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 5 | Gene Therapy × LADA | 100.0 | 0 | Partial — Literature Synthesis |

**Doctrine Alignment:** Gaps #3 and #1/#4 directly map to Tier 1 contribution areas (Drug Repurposing Computational Screening and Epidemiological Data Analysis). Gap #5 is relevant given LADA's persistently low publication activity (only 9 papers in 30-day PubMed window).

**Validation level:** BRONZE (single analytical source — per Research Doctrine, requires expert confirmation).

---

## Breaking News (Web Search — March 24–31, 2026)

### Continuing Major Developments (previously reported, still active)

| Item | Date | Evidence Level | Status |
|------|------|---------------|--------|
| **Awiqli (Insulin Icodec) — FDA APPROVED** | Mar 27 | Regulatory action (G) | First once-weekly basal insulin for T2D. Novo Nordisk. Launch H2 2026. |
| **Wegovy HD (Semaglutide 7.2 mg) — FDA APPROVED** | Mar 19 | Regulatory action (G) | Higher-dose semaglutide for weight management. |
| **Retatrutide Phase 3 (TRANSCEND-T2D-1)** | Mar 19 | 1b (Phase 3 RCT) | Triple agonist: 2.0% A1C reduction, 16.8% weight loss. |
| **Stanford T1D Remission (preclinical)** | Mar 28 | 5 (animal model) | Double cell transplant: 100% remission in mice. Human trials planned. |
| **ADA Standards of Care 2026** | Late Mar | Clinical guideline (S) | Includes GLP-1 RA for obesity in T1D (new Rec 8.29), expanded SGLT2i/GLP-1 in CKD. |

### NEW — Upcoming FDA Decisions (Q2 2026) ⚠️ HIGH PRIORITY

| Drug | Sponsor | PDUFA Date | Indication | Significance |
|------|---------|------------|------------|-------------|
| **Orforglipron** | Eli Lilly | **April 10, 2026** | Oral GLP-1 RA for T2D | First-in-class oral non-peptide GLP-1. Game-changer if approved. Key tracked therapy. |
| **Teplizumab (Tzield) sNDA** | Sanofi | **April 29, 2026** | Delay Stage 3 T1D in at-risk patients ≥8 yrs | Expanded indication for T1D prevention. Key tracked therapy. |
| **Afrezza (pediatric)** | MannKind | **May 29, 2026** | Inhaled insulin for children ages 4–17 | First inhaled insulin for pediatric T1D/T2D. Relevant to Youth Diabetes domain. |

### New Finding — Oral Insulin Pill Breakthrough

Researchers at Kumamoto University have developed a peptide that enables insulin absorption through the intestinal wall, potentially enabling oral insulin delivery. This is preclinical (Evidence Level 5) but could transform insulin delivery if validated in human trials.

---

## Recommended Actions

### Immediate (Today/This Week)

1. **🔴 Re-run gap analysis — data is now 16 days old, past threshold.**
   → `Run: python project1_literature_gap_analysis.py`

2. **🔴 Add Q2 2026 FDA decision dates to tracker:**
   - Orforglipron PDUFA: April 10, 2026
   - Teplizumab sNDA PDUFA: April 29, 2026
   - Afrezza pediatric PDUFA: May 29, 2026
   These are time-sensitive and should be tracked as priority items.

3. **Review triple-domain cross-over paper (PMID 41907858)** — "Oral and cardiometabolic health through the lens of biobanks" spans T2D Remission + Microbiome + Multi-Omics. Directly aligns with Tier 1 Multi-Omics Biomarker Integration.

4. **Confirm AI/ML domain recovery** — The PubMed API issue from yesterday (AI/ML dropping to 0) appears resolved (now showing 221 papers). No script changes needed, but note in tracker log.

### This Week

5. **Review teplizumab real-world experience paper (PMID 41796109)** — Timely given the April 29 FDA decision for expanded indication. Clinical practice data supplements trial evidence.

6. **Review verification report outputs** — 34 new verification reports were generated. Check `Analysis/Results/verification_reports/verification_summary.json` for any flagged issues requiring attention. Several dashboards were quarantined (CART_Access_Barriers, GKA_Pricing, Generic_Drug_Catalog, Research_Paths).

7. **Review quarantined dashboards** — 4 dashboards moved to `Dashboards/_quarantine/`. Determine what failed verification and whether they should be fixed and restored or archived.

### Ongoing Monitoring

8. **All automated scripts ran successfully** — hub_monitor.py, baseline_clinical_trials.py, and baseline_pubmed_alerts.py all produced fresh outputs on 2026-03-31. No script re-runs needed except gap analysis.

9. **Baricitinib Phase 3 trials** (NCT07222137, NCT07222332) — Still actively recruiting. Continue high-priority tracking.

10. **Watch for orforglipron FDA decision** — April 10 is 10 days away. Prepare tracker update for either approval or CRL.

11. **Watch for Stanford T1D human trial registration** — Following preclinical announcement March 28.

12. **Watch for aleniglipron Phase 3 trial registration** — Expected H2 2026 on ClinicalTrials.gov.

---

*Report generated: 2026-03-31 | Next scheduled scan: 2026-04-01*
*Methodology: Research Doctrine v1.0 | Validation standards applied to all new claims*

Sources:
- [FDA Approves Awiqli](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html)
- [Stanford T1D Remission Breakthrough](https://nationaltoday.com/us/ca/stanford/news/2026/03/28/stanford-researchers-announce-breakthrough-in-type-1-diabetes-remission/)
- [ADA Standards of Care 2026](https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2026)
- [Q2 2026 FDA Decisions to Watch](https://www.patientcareonline.com/view/5-fda-decisions-to-watch-for-q2-2026)
- [6 FDA Decisions to Watch Q2 2026](https://www.biospace.com/fda/6-fda-decisions-to-watch-in-q2-2026)
- [Oral Insulin Pill Breakthrough](https://www.sciencedaily.com/releases/2026/03/260324024302.htm)
- [MUSC T1D Cure Plan](https://www.sciencedaily.com/releases/2026/03/260302030648.htm)
- [GLP-1 RA News March 2026](https://www.hcplive.com/view/diabetes-dialogue-glp-1-ra-news-updates-in-march-2026)
